In genetic screens aimed at understanding drug resistance mechanisms in chronic myeloid leukemia cells, inactivation of the cullin 3 adapter protein-encoding leucine zipper-like transcription regulator 1 (LZTR1) gene led to enhanced mitogen-activated protein kinase (MAPK) pathway activity and reduced sensitivity to tyrosine kinase inhibitors. Knockdown of the Drosophila LZTR1 ortholog CG3711 resulted in a Rasdependent gain-of-function phenotype. Endogenous human LZTR1 associates with the main RAS isoforms. Inactivation of LZTR1 led to decreased ubiquitination and enhanced plasma membrane localization of endogenous KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog). We propose that LZTR1 acts as a conserved regulator of RAS ubiquitination and MAPK pathway activation. Because LZTR1 disease mutations failed to revert loss-of-function phenotypes, our findings provide a molecular rationale for LZTR1 involvement in a variety of inherited and acquired human disorders.
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C hronic myeloid leukemia (CML) is characterized by the expression of the constitutively active oncogenic tyrosine kinase fusion BCR-ABL (1) . The proliferation and survival of BCR-ABL + CML cells depends on the activation state of key cellular signaling networks, including the mitogen-activated protein kinase (MAPK) pathway (1) . The development of the tyrosine kinase inhibitor (TKI) imatinib has provided a successful targeted therapeutic, however limited by the development of resistance (2) .
Genetic screens in the near-haploid human CML cell line KBM-7 allow unbiased identification of candidate genes that affect inhibitor resistance (3) . We performed comprehensive haploid genetic screening with six TKIs in clinical use or under evaluation (fig. S1A). Retroviral genetrap mutagenized cells were exposed to the TKIs at concentrations corresponding to half maximal inhibitory concentration (IC 50 ) to IC 70 dosage (fig. S1B), resistant cell populations were collected after selection, and genomic gene-trap insertions were identified by means of deep sequencing. Each screen resulted in enrichment of disruptive insertions in 5 to 18 different genes ( Fig. 1A; figs. S1, C to G, and S2A; and table S1). We identified a recurrent set (≥4 screens) of six genes (NF1, WT1, PTPN1, PTPN12, LZTR1, and BAP1; "TOP6" set) (Fig. 1B) with overrepresentation of disruptive genomic gene-trap integrations, strongly indicating a selective advantage upon drug treatment ( fig. S2B ).
We used a lentiviral CRISPR/Cas9 multicolor competition assay (MCA)-based coculture system to evaluate gene-mediated drug-resistance effects. SpCas9-expressing KBM-7 (KBM-7
Cas9 ) cells were infected with lentiviral single-guide RNA (sgRNA) vectors that coexpress reporter fluorophores, which enabled the tracing of knockout and control cell populations by means of flow cytometry in the same well ( fig. S3A ). Mixed sgRen (targeting Renilla luciferase) control cell populations that express fluorescent proteins (GFP + or mCherry + ) did not show any preferential outgrowth of resistant cells upon 14 days of TKI treatment (Fig. 1C and fig. S3H ). By contrast, KBM-7
Cas9 GFP + cells harboring sgRNAs that target the TOP6 genes showed a decreased amount of cognate protein ( fig. S3 , B to G) and demonstrated enhanced cell survival and outgrowth in the presence of imatinib (Fig. 1C) and rebastinib ( fig. S3H ). Thus, we functionally validated the TOP6 genes as important for drug action in BCR-ABL + CML cells. Although NF1, PTPN1, and PTPN12 share the ability to modulate MAPK pathway activation, and WT1 as well as BAP1 function through transcriptional regulation ( fig. S2C ), we could not deduce any mechanistic explanation for the role of leucine zipper-like transcription regulator 1 (LZTR1) in enhanced CML cell survival from the existing literature (4, 5). To exclude cell line-specific effects, we confirmed that loss of LZTR1 expression induced resistance to imatinib and rebastinib in other CML cell lines ( fig. S4 , A to C). Although we identified significant LZTR1 enrichment only in four of the genetic screens, KBM-7
Cas9 sgLZTR1 cells exhibited various degrees of resistance against all tested BCR-ABL TKIs ( fig.  S3I ). We used a CRISPR/Cas9-based domain scanning strategy to test whether both N-terminal Kelch domains and C-terminal Broad-Complex, Tramtrack, and Bric a brac (BTB) and partial BACK domains are essential for the drug-resistance phenotype (6) (7) (8) . All protein domain-targeting sgRNAs showed efficient indel formation ( fig. S3J ) and induced resistant outgrowth of targeted cell populations exposed to rebastinib, indicating that the entire protein is functionally required (fig. S3K ). To determine whether LZTR1 exerts its function only in a CML-specific context, we infected FLT3-ITD + acute myeloid leukemia (AML) MV4-11
Cas9 cells with LZTR1, targeting sgRNAs ( fig. S4D ). FLT3 inhibitor treatment led to an outgrowth of resistant cells, underlining a more general role for LZTR1 in the drug response of hematopoietic cancers driven by different tyrosine kinases ( fig. S4 , E to G).
KBM-7
Cas9 CML cells infected with distinct sgRNAs targeting LZTR1 displayed enhanced phosphorylation of MAPK kinase 1 (MEK1) and -2 and extracellular signal-regulated kinase 1 (ERK1) and -2, which is indicative of augmented MAPK pathway activation ( Fig. 2A) . By contrast, global tyrosine phosphorylation as well as phosphorylation of AKT (at S473 and T308), the protein kinase S6K1, ribosomal protein S6, and the direct BCR-ABL substrate signal transducer and activator of transcription 5 (STAT5) remained unchanged ( fig. S4 , J and K). Additional CML (K-562 and LAMA-84) and AML (MV4-11) cell lines had similarly enhanced MAPK pathway activation under normal growth conditions as well as, in the case of CML cells, upon increasing concentration of imatinib treatment ( Fig. 2A and figs. S4, H and I, and S5, A to C). LZTR1 fulllength cDNA complementation in K-562 Cas9 sgLZTR1 cells reverted both enhanced MEK and ERK phosphorylation as well as TKI resistance (Fig. 2, B 
and C). Treatment of K-562
Cas9 sgLZTR1 cells with the clinically approved inhibitor of MEK1 and -2 trametinib reverted enhanced activation of ERK1 and -2 and pharmacologically counteracted the drug-resistance phenotype (Fig. 2, D and E) . Furthermore, cDNA expression of constitutively active Mek1 D218, D222 (Mek1 DD) in K-562 rtTA3 cells led to enhanced phosphorylation of ERK1 and -2 and reduced imatinib sensitivity ( fig. S6A, and B) . Activation of the MAPK pathway could also be inferred by the gene expression and transcription factor enrichment signature obtained with RNA sequencing experiments in Cas9 sgLZTR1 compared with sgRen cells (fig. S5, D and E, and table S2). Altogether, the data established a causal role for enhanced MAPK pathway activation in the resistance of CML cells toward TKI therapy as elicited by loss of LZTR1 function.
Because BTB domain-containing proteins serve as adaptor proteins for the cullin 3 (CUL3) E3 ubiquitin ligase complex, enabling specific substrate recognition and ubiquitination (9), we tested whether loss of CUL3 expression could mimic the observed LZTR1 loss-of-function phenotype. K-562 Cas9 sgCUL3 cells demonstrated enhanced MAPK pathway activation and, in contrast to sgLZTR1 cells, increased phosphorylation of AKT ( fig. S4K ). However, sgRNAs that target CUL3 had a pronounced antiproliferative effect both in KBM-7
Cas9 and K-562 Genetic studies have identified LZTR1 mutations in glioblastoma (GBM) (11), schwannomatosis (SWNMT) (8) , and Noonan syndrome (NS) (5), a developmental syndrome that is part of the larger group of RASopathies characterized by mutations in components of the RAS-MAPK pathway (12) . Identification of NF1 and LZTR1 loss-of-function-induced MAPK pathway activation in our haploid resistance screens combined with human LZTR1 mutations in NS indicated that LZTR1 might directly regulate guanosine triphosphatases (GTPases) of the RAS family.
Drosophila wing vein formation and eye development serve as excellent in vivo readouts for RAS signaling (13) (14) (15) CML cells transduced with sgRNAs targeting the "TOP6" genes or sgRen.208 (targeting Renilla luciferase) as negative control. sgRNAinfected cell populations were mixed in a 1:1 ratio, treated with increasing drug concentrations, and analyzed by means of flow cytometry after 14 days. Data are shown as mean value ± SD of at least two independent experiments (n ≥ 2) performed in duplicates. sgRNAs are labeled by gene name followed by the genomic targeting sequence position numbered according to the sequence position on the corresponding mRNA.
acids 1 to 184) that is only found in Drosophila. This is followed by the highly conserved remaining part of the protein (54% sequence identity) ( fig. S8 , A to C). Systemic depletion of CG3711 with RNA interference (RNAi) by using act5C-Gal4 yielded viable flies; however, the majority of wings of these flies displayed wing vein defects characterized by extra veins and vein tissue (Fig. 3, A and B, and fig. S8D ). This phenotype closely resembles a gain-of-function increase of RAS-MAPK signaling (15) and could be rescued by a decrease in abundance of RAS via dRas (Drosophila Ras) heterozygosity (Fig. 3C) . Drosophila R7 photoreceptor induction requires RAS function (13, 14) . We used a mild dominant negative version, Ras V12C40 , which although locked in the active guanosine 5′-triphosphate (GTP)-bound state does not activate MAPK signaling (16) . Ras V12C40 expression in the developing eyes (via the sevenless/sev-Gal4 expression system) led to a frequent loss of the R7 photoreceptor (~30% of ommatidia display R7 loss, and some also lost other R-cells) ( fig. S8 , E and H). Because Ras V12C40 is constitutively active, it also causes defects in ommatidial rotation (16, 17) , serving as internal control. When both sev-Gal4-driven CG3711 RNAi and Ras V12C40 were expressed, the loss of R7 phenotype was almost completely suppressed ( fig. S8, F and H and (D) are representative of at least two independent biological experiments (n ≥ 2). MCA data in (C) and (E) are shown as mean value ± SD of at least two independent experiments (n ≥ 2). Dimethyl sulfoxide (DMSO) treatment served as negative control.
rather than suppressed because these involve MAPK-independent RAS signaling ( fig. S8F ) (16) . Expression of CG3711 RNAi in the eye alone did not induce phenotypic changes (fig. S8, G and H). Thus, RAS is crucial for the phenotypes induced by depletion of CG3711.
To explore possible interactions of LZTR1 with RAS, we used a BirA* fusion protein-based proximity biotinylation-dependent (BioID) proteomic approach, which allows identification of weak interaction partners. We expressed KRAS4A, KRAS4B, NRAS, and HRAS as N-terminal FLAGBirA* fusion proteins in K-562 rtTA3 CML cells. This led to enhanced MEK and ERK activation, demonstrating that the BirA* tag does not generally interfere with RAS signaling (fig. S9A) . We identified between 153 and 258 proteins in proximity of or interacting with human RAS proteins, among them several known interactors and pathway components ( fig. S9, B BioID proximity biotinylation-based and FLAG tag-based coimmunoprecipitation experiments confirmed the interaction of all four RAS proteins with endogenous LZTR1 (fig. S10, B and C) . Only the four main RAS isoforms interacted specifically with LZTR1, whereas six related RAS family GTPases showed no interaction ( fig. S11A ). Nine other canonical positive RAS-MAPK pathway regulators also failed to interact with endogenous LZTR1 (fig. S11B ). Immunoprecipitations with extracts derived from LZTR1 knockout cells confirmed the specificity of the interaction (fig.  S11C ). The C-terminal posttranslational acylations of KRAS proteins appeared to be required for the interaction with LZTR1 (Fig. 3D and fig.  S11D ). Thus, proper membrane-associated localization mediated by this region may be required for specific interaction with LZTR1.
Stably expressed full-length hemagglutinin (HA)-tagged LZTR1 protein showed a speckled and vesicular staining pattern in HeLa, HEK293T, and HAP1 cells, whereas all domain mutants had a homogenous cytoplasmic distribution ( fig. S12,  A to D) . Full-length LZTR1 displayed an overlapping localization within speckled and vesicular compartments with transiently transfected V5-tagged CUL3 in HeLa cells (fig. S13A ). The LZTR1-stained speckles further overlapped with the autophagosome marker LC3B fused to mCherry ( fig. S13B ), but we failed to detect LZTR1 localization with marker proteins of the Golgi, lysosome, peroxisome, or early and late endosome compartments ( fig. S13C ). Isoform-specific antibodies that recognize endogenous human RAS isoforms are not available (19) . We therefore endogenously tagged KRAS ( fig. S14A ) and confirmed specificity of detection in immunofluorescence and immunoblotting by means of genetic inactivation of the tagged genomic allele ( fig. S14, B to D) . KRAS localized to a large number of small-punctate structures, likely membrane-containing small vesicles (Fig. 3E and  fig. S14D ). Inactivation of endogenous LZTR1 led to an increased RAS signal, particularly at the periphery of cells, at regions of cell-to-cell contacts (Fig. 3E and fig. S14D ). This phenotype appeared to be dependent on the CUL3 E3 ligase complex because genetic inactivation of CUL3 led to similar phenotypic changes (Fig. 3E and  fig. S14E ).
We also assessed interaction of endogenously tagged KRAS with exogenous LZTR1 in HAP1 cells ( fig. S15A ). Exogenous LZTR1 localized to fewer, larger, and more oblong structures than did endogenous KRAS ( fig. S15B) . A fraction of the LZTR1-stained structures also contained KRAS. Treatment with the cullin neddylation inhibitor MLN4924 caused clustering of LZTR1-containing structures that appeared to surround particles strongly stained with KRAS ( fig. S15B , MLN4924 panel). Caution is required for the interpretation of these patterns because LZTR1 was overexpressed, and KRAS was at endogenous concentration. However, the images could represent a trapped proteostatic process that involves the two proteins.
We tested whether LZTR1 affected ubiquitination of RAS proteins by acting as a substrate adaptor for the CUL3 E3 ligase complex (11, 20) . Ubiquitination of RAS proteins is known, but little is known of its consequences (21) (22) (23) (24) (25) . Coexpression of HA-ubiquitin with either one of the four RAS isoforms alone only resulted in a basal state of ubiquitination, but addition of MYC-tagged CUL3 and V5-tagged LZTR1 led to increased ubiquitination of RAS proteins ( fig.  S16, A to D) . LZTR1-deletion mutants that lack either one or both C-terminal BTB domains or the N-terminal Kelch domain failed to induce an equivalent degree of ubiquitination of KRAS4A ( fig. S16A) . KRAS4A required the presence of its C-terminal hypervariable region (HVR) and the farnesylated cysteine 186 for LZTR1-mediated ubiquitination ( fig. S16E ). LZTR1-induced ubiquitination was unchanged in cells treated with a proteasome inhibitor but could be blocked by cullin neddylation inhibition, which is consistent with the observed subcellular localization changes ( fig. S16F ). Specificity for LZTR1 in the process was further underscored by the failure of two prominent CUL3 adaptors, Kelch-like ECHassociated protein 1 (KEAP1) and Speckle-type POZ protein (SPOP), to cause a comparable ubiquitination ( fig. S16G ). We used HAP1 cells that bear endogenously tagged KRAS and tandem ubiquitin binding domain (TUBE) reagents to capture endogenously ubiquitinated proteins and evaluate the contribution of endogenous LZTR1 (26) . In the absence of any stimulation, immunoprecipitation with TUBE purified several proteins that reacted with pan-ubiquitin antibodies (Fig.  3F, third from top, and fig. S16H ). The same precipitates contained proteins that react with pan-RAS antibodies (Fig. 3F, second from top) . Last, FLAG antibodies detected a protein not visible in the whole-cell extract (Fig. 3F, top, and fig. S16H ). TUBE-mediated immunoprecipitation from corresponding cells in which LZTR1 had been genetically inactivated did not contain amounts of RAS detectable with these antibodies (Fig. 3F,  top and second from top, and fig. S16H ). The signal obtained with pan-ubiquitin antibodies was unchanged (Fig. 3F, third from top, and fig.  S16H ). Thus, human LZTR1 appears to mediate ubiquitination of endogenous human KRAS and possibly other RAS proteins.
If a main function of LZTR1 is to regulate RAS, then loss of RAS function should compensate for loss of LZTR1 activity, as suggested in the fruitfly epistatic analysis, representing an ideal experimental setup to assess the disease-associated LZTR1 mutations by their dependency on RAS activity. We confirmed that loss of LZTR1 function enhanced RAS activity in K-562 cells (fig. S17A). We then performed CRISPR/Cas9-based double-knockout MCA experiments ( fig. S17 , B to D). Single sgLZTR1 and sgLZTR1-sgRen doubleinfected cells were resistant to imatinib compared with control sgRen cells (fig. S17, E and F). sgRNAs that target KRAS abolished cellular outgrowth, whereas sgRNAs that target NRAS, HRAS, and RIT1 failed to do so (fig. S17, E and F). sgLZTR1-sgKRAS cells had reduced MEK phosphorylation comparable with that of sgRen cells, whereas sgNRAS and sgHRAS cells maintained enhanced MAPK pathway activation ( fig. S17G ). KRAS inactivation led to a strong antiproliferative phenotype in KBM-7
Cas9 cells and, to a lesser extent, K-562
Cas9 cells ( fig. S18, A and B) , indicating that the selective requirement of KRAS in mediating LZTR1-induced enhanced MAPK pathway activation might represent a prerequisite of KRAS for BCR-ABL signaling in CML cells. We additionally used a fibronectin-fold-based monobody, NS1, which bears low nanomolar affinity for the dimerization interface of both KRAS and HRAS and is able to interfere with their signaling activities (27) . Cells that stably express the NS1 monobody did not show increased activation of the MAPK pathway or drug resistance associated with loss of LZTR1 function (fig. S18, C and D).
More than 50 different mutations have been mapped to the human LZTR1 gene in various diseases ( fig. S19, A and B, and table S5) (5, 8, 11, (28) (29) (30) . To establish a mechanistic link between mutations that affect human diseases and the biochemical processes described here, we focused on LZTR1 missense mutations identified in GBM (11), NS (5), and SWNMT (8) (fig. S20B ). Mutationbearing LZTR1 cDNAs were tested for their ability to complement K-562 CML cells deficient in endogenous LZTR1 (fig. S20A) . In contrast to WT LZTR1, the disease-associated mutations failed to reduce MAPK pathway activation, despite being expressed at a comparable or higher amount (Fig. 4, A to C) . Similarly, all missense mutations apart from the GBM-associated T288I and R810W failed to restore sensitivity to imatinib treatment (fig. S20, C to E). LZTR1 mutations within the Kelch domain partially retained their localization pattern in comparison with the WT protein, whereas mutations in the BTB/BACK domains mislocalized to the cytoplasm ( fig. S21, A and B) . In agreement, expression of LZTR1 Kelch domain mutations identified in GBM, NS, and SWNMT in K-562 WT cells had a resistance-mediating effect in MCA assays in cells treated with imatinib, whereas BTB/BACK domain mutations did not ( fig. S22 , A to C). Furthermore, in contrast to the LZTR1 WT protein, the two mutants R198G and G248R identified in GBM and NS failed to induce a similar increase in ubiquitination on KRAS4A ( fig. S22D ). These findings provide functional evidence that human LZTR1 missense mutations identified in GBM, NS, and SWNMT represent loss-of-function toward ubiquitination and inhibition of RAS activity.
Together with the accompanying manuscript on the role of LZTR1 in diseases driven by the dysregulation of RAS ubiquitination and signaling (31), our work illustrates the importance of an additional, underappreciated layer of RAS regulation (Fig. 4D) . 
